First-line endocrine therapy for advanced breast cancer. A real-world study at a Latin American university health institution-Reference-Cited by-同舟云学术

First-line endocrine therapy for advanced breast cancer. A real-world study at a Latin American university health institution

Published:2020-05-14 Issue:7 Volume:36 Page:1195-1199
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Walbaum Benjamin¹,Acevedo Francisco¹,Medina Lidia²,Bravo M. Loreto¹,Merino Tomas¹,Camus Mauricio³,Dominguez Francisco³,Mondaca Sebastian¹,Galindo Hector¹,Nervi Bruno¹,Ibañez Carolina¹,Madrid Jorge¹,Peña Jose¹,Koch Erica¹,Garrido Marcelo¹,Pinto Mauricio P.¹,Sánchez César¹

Affiliation:

1. Department of Hematology-Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile;

2. Centro de cáncer Red Red de Salud UC Christus, Pontificia Universidad Católica de Chile, Santiago, Chile;

3. Department of Surgical Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2020.1763282

Reference20 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

3. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis

4. Current Treatment Patterns Among Postmenopausal Women with HR+/HER2− Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors;Clinical Breast Cancer;2021-12

2. Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer;Breast Cancer Research and Treatment;2021-10-23

3. Treatment and Monitoring Variability in US Metastatic Breast Cancer Care;JCO Clinical Cancer Informatics;2021-05